L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem białaczki szpikowej (AML) zgodnie z międzynarodowymi standardami
- •Białaczka, która nie odpowiada na pierwsze leczenie lub powróciła po pierwszym leczeniu
- •Wiek od 18 do 80 lat
- •Nie otrzymywał chemioterapii, radioterapii lub dużej operacji w ciągu 2 tygodni przed rozpoczęciem badania, lub całkowicie wyzdrowiał z powikłań poprzedniego leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (28)
University of Alabama Birmingham
Birmingham, United States
Bioresearch Partners
Miami, United States
Augusta University - Georgia Cancer Center
Augusta, United States
University of Nebraska Medical Center
Omaha, United States
Atlantic Health
Morristown, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
University of Pennsylvania
Philadelphia, United States
University of Rhode Island
Providence, United States
Fakultní nemocnice Hradec Králové
Hradec Králové, Czechia
GEORGIA: LLC ARENSIA Exploratory Medicine
Tbilisi, Georgia
Caucasus Medical Center
Tbilisi, Georgia
RCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia
Bologna, Italy
AOU Careggi
Florence, Italy
AUSL della Romagna - Santa Maria delle Croci - Ravenna
Ravenna, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart
Roma, Italy
LSMU Kauno klinikos
Kaunas, Lithuania
Szpital Kliniczny MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku
Olsztyn, Poland
Oddział Hematologii i Transplantacji Szpiku, Uniwersytecki Szpital Kliniczny w Poznaniu
Poznan, Poland
Uniwersytecki Szpital Kliniczny Klinika Hematologii i Transplantologii (Szczecin)
Szczecin, Poland
Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddział Hematologii
Torun, Poland
Instytut Hematologii i Transfuzjologii, Klinika Hematologii
Warsaw, Poland
ARENSIA research clinic at the Oncology Institute "Prof. Dr. Ion Chiricuţă"
Cluj-Napoca, Romania
Institut Català d'Oncología (ICO) - Hospital Germans Trias i Pujol
Barcelona, Spain
Hospital Universitario Central de Asturias (HUCA)
Oviedo, Spain
Hospital MD Anderson Cancer Center Madrid
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario La Fe de Valencia
Valencia, Spain
ARENSIA Exploratory Medicine, LLC
Kyiv, Ukraine
Trial contact
Paul Waymack, MD, Sc.D
Erikson Wasyl, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.